Compare UVE & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | ALVO |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | N/A |
| Metric | UVE | ALVO |
|---|---|---|
| Price | $43.57 | $4.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $8.00 |
| AVG Volume (30 Days) | 222.8K | ★ 698.9K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 3.93 | N/A |
| Revenue | ★ $1,603,915,000.00 | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | $2.88 | $18.63 |
| P/E Ratio | $23.43 | ★ $18.20 |
| Revenue Growth | ★ 5.48 | N/A |
| 52 Week Low | $22.87 | $2.94 |
| 52 Week High | $45.15 | $9.25 |
| Indicator | UVE | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 59.65 |
| Support Level | $29.85 | $3.65 |
| Resistance Level | $43.68 | $3.94 |
| Average True Range (ATR) | 1.60 | 0.19 |
| MACD | 0.43 | 0.05 |
| Stochastic Oscillator | 79.50 | 96.48 |
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.